Related Experiment Video
Updated: Feb 26, 2026
A Procedure to Study the Effect of Prolonged Food Restriction on Heroin Seeking in Abstinent Rats
Published on: November 11, 2013
Endocrinopathies and Their Recovery in a 20-Year Cohort Study of People With Heroin Dependence
Chris Tremonti1,2, Stephen M Twigg2,3, Katherine L Mills4
1St Vincent's Hospital, Sydney, NSW, 2011, Darlinghurst, Australia.
Objective:
Chronic opioid use suppresses hypothalamic-pituitary signalling, leading to hypogonadism and adrenal insufficiency. Whether these abnormalities persist following long-term opioid cessation remains unclear. In particular, data on the female gonadal axis are limited, while other endocrine outcomes are predominantly reported in male cohorts. This study examined endocrine function in a long-term prospective cohort of people with opioid use disorder, comparing those in sustained remission with those continuing opioid use, exploring associations with opioid exposure, sex and depression.
Design:
Prospective cohort study using data from the Australian Treatment Outcome Study 18-20 year follow-up.
Patients And Measurements:
Participants underwent a structured interview and fasting endocrine assessment, including gonadal, adrenal, thyroid, and prolactin measurements. Endocrinopathies were defined using prespecified biochemical and clinical criteria. Prevalence was compared between opioid-free and opioid-using participants. Associations with opioid exposure, sex and depression were examined using Firth logistic regression.
Results:
Among 123 participants with complete endocrine data, 71 (57.7%) had at least one endocrinopathy. Thirty-five participants (28.4%) were opioid-free. Hypogonadism was markedly less common in opioid-free participants (3.3% vs. 26.7%), and no opioid-free participant had hypocortisolism, compared with 14.8% of those with continuing opioid use. Methadone dose, male sex, and depression were independently associated with hypogonadism. Men prescribed methadone had significantly lower testosterone and luteinising hormone levels. No participant with hypogonadism or hypocortisolism had been previously diagnosed or treated.
Conclusions:
Opioid-induced endocrine suppression appears reversible with sustained opioid abstinence. Higher methadone dose, male sex, and depression were associated with hypogonadism. Despite frequent healthcare contact, patients remained undiagnosed, highlighting a gap in clinical awareness of opioid-associated endocrinopathies and the need for routine screening in opioid agonist treatment settings.
Insights
Opioid-induced hypogonadism and adrenal insufficiency may resolve after stopping opioids. Sustained opioid abstinence appears reversible, but higher methadone doses, male sex, and depression are linked to hypogonadism.
Area of Science:
- Endocrinology
- Addiction Medicine
- Public Health
Background:
- Chronic opioid use is known to disrupt hypothalamic-pituitary signaling, causing hypogonadism and adrenal insufficiency.
- Limited data exist on the persistence of these endocrine abnormalities after long-term opioid cessation, particularly concerning the female gonadal axis.
Purpose of the Study:
- To investigate endocrine function in individuals with opioid use disorder, comparing those in sustained remission versus those continuing opioid use.
- To explore associations between endocrine outcomes, opioid exposure, sex, and depression in a long-term prospective cohort.
Main Methods:
- Prospective cohort study utilizing 18-20 year follow-up data from the Australian Treatment Outcome Study.
- Participants underwent structured interviews and fasting endocrine assessments (gonadal, adrenal, thyroid, prolactin).
- Endocrinopathies were defined by biochemical and clinical criteria; prevalence compared between opioid-free and opioid-using groups using Firth logistic regression.
Main Results:
- Of 123 participants, 71 (57.7%) had at least one endocrinopathy.
- Hypogonadism was significantly less common in opioid-free participants (3.3% vs. 26.7%), and hypocortisolism was absent compared to 14.8% in the opioid-using group.
- Higher methadone dose, male sex, and depression were independently associated with hypogonadism; no participants had prior diagnosis or treatment for their condition.
Conclusions:
- Opioid-induced endocrine suppression appears reversible with sustained opioid abstinence.
- Higher methadone dose, male sex, and depression are risk factors for persistent hypogonadism.
- Lack of diagnosis highlights a critical need for routine endocrine screening in opioid agonist treatment settings.
More Related Videos
Related Concept Videos
01:17Classification of Illness
An illness is a response to a disease in which the person's level of functioning is changed compared with a previous level. The general classification of illness includes acute and chronic.
Acute illness is severe...
01:17Drug Dependence
01:15Drug Abuse and Addiction: Pharmacological Phenomena
01:24Substance Use Disorders Affecting Sleep
Understanding the concepts of physical dependence,...
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:21Drug Accumulation During Multiple Dosing: Repetitive IV Injections